0.6256

2.87% -0.0185

After Hours: .63 0.0044 +0.70%

Calidi Biotherapeutics Inc (CLDI)

Overview News Price History Discussions Forecast

Calidi Biotherapeutics Inc stock is traded at $0.6256, with a volume of 854.58K. It is down -2.87% in the last 24 hours and down -48.72% over the past month. Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.

Previous Close:

$0.6441

Open:

$0.6369

24h Volume:

854.58K

Relative Volume:

0.47

Market Cap:

$16.10M

Revenue:

Net Income/Loss:

$-23.36M

P/E Ratio:

-0.8491

EPS:

-0.7368

Net Cash Flow:

1W Performance:

-17.79%

1M Performance:

-48.72%

6M Performance:

-60.90%

1Y Performance:

-92.77%

1-Day Range:

$0.58

$0.6483

1-Week Range:

$0.58

$0.78

52-Week Range:

$0.58

$16.80

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Name

Calidi Biotherapeutics Inc

Sector

Healthcare (1178)

Industry

Biotechnology (678)

Phone

(858) 794-9600

Address

4475 Executive Drive, Suite 200, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CLDI's Discussions on Twitter

Compare CLDI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDI Calidi Biotherapeutics Inc	0.6256	16.10M	0	-23.36M	0	-0.7368
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-22-23	Initiated	H.C. Wainwright	Buy
Oct-09-23	Initiated	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Stock (CLDI) Latest News

10:16 AM

CLDI Stock Plummets to 52-Week Low at $0.6 Amid Market Turbulence - Investing.com

10:16 AM

02:05 AM

Calidi Biotherapeutics Bolsters Cash Balance and Terminates Standby Equity Purchase AgreementSAN DIEGO, January 28, 2025 – Calidi Biotherapeutics Inc. (NYSE American: CLDI) recently disclosed the ending cash balance amounting to approximately $ - Defense World

02:05 AM

Jan 29, 2025

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 - The Manila Times

Jan 29, 2025

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - GlobeNewswire

Jan 29, 2025

Inside Calidi's Game-Changing Cancer Treatment Pipeline: Top Execs Reveal Next-Gen Therapies - StockTitan

Jan 29, 2025

Jan 28, 2025

CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 28, 2025

Calidi Biotherapeutics Ends SEPA After Successful Fundraising - TipRanks

Jan 28, 2025

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement - GlobeNewswire

Jan 28, 2025

Cancer Biotech Raises $18.8M War Chest to Fast-Track Revolutionary Brain Cancer Treatment - StockTitan

Jan 28, 2025

Jan 25, 2025

Why Calidi Biotherapeutics Inc (AMEX: CLDI) Is A Great Stock Pick For Momentum Investors - Stocks Register

Jan 25, 2025

Jan 22, 2025

CLDI stock touches 52-week low at $0.73 amid market challenges - MSN

Jan 22, 2025

Jan 15, 2025

The Business Case For Buying Calidi Biotherapeutics Inc (AMEX: CLDI) Stock Now - Stocks Register

Jan 15, 2025

Jan 13, 2025

Calidi Biotherapeutics Announces Presentation of New Data - GlobeNewswire

Jan 13, 2025

Calidi Biotherapeutics to Present Breakthrough Cancer Treatment Platform at AACR 2025 Meeting - StockTitan

Jan 13, 2025

Calidi Biotherapeutics announces reverse stock split adjustment - Investing.com

Jan 13, 2025